Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

A test series with vitamin D proved that mycobacterial growth control by human immune cells can be measured by the MGIA: in PBMC and BALC, M. tuberculosis grew slower in the presence of vitamin D, which is reflected by the estimated 17.2 h higher TTP in PBMC (95% CI: 13.4 to 21.0 h, p < 0.0001) and 20.6 h higher TTP in BALC (95% CI: 16.8 to 24.3 h, p < 0.0001, Figure 6A), as well as in the 0.441 lower log10 CFU count in PBMC (95% CI: −0.524 to −0,359, p < 0.0001) and 0.226 log10 CFU count in BALC (95% CI: −0.348 to −0.184, p < 0.0001, Figure 6B).

Source: Vitamin D Supplementation. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

At both time points, BALC and PBMC were in vitro infected with M.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Mycobacterium Growth Inhibition Assay of Human Alveolar Macrophages as a Correlate of Immune Protection Following Mycobacterium bovis Bacille Calmette-Guérin Vaccination

Study design awaiting verification · Frontiers in Immunology · 2018

Original publication title

Mycobacterium Growth Inhibition Assay of Human Alveolar Macrophages as a Correlate of Immune Protection Following Mycobacterium bovis Bacille Calmette: Guérin Vaccination

Juliane Radloff; Jan Heyckendorf; Lize van der Merwe; Patricia Sanchez Carballo; Norbert Reiling; Elvira Richter; Christoph Lange; Barbara Kalsdorf

Copyright © 2018 Radloff, Heyckendorf, van der Merwe, Sanchez Carballo, Reiling, Richter, Lange and Kalsdorf.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In conclusion, M. bovis BCG-vaccination-induced mycobacterial-specific cytokine immune response does not result in functional immune control against M. tuberculosis in the MGIA.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

In order to eliminate tuberculosis (TB), an effective vaccine is urgently needed to prevent infection with Mycobacterium tuberculosis. A key obstacle for the development of novel TB vaccines is the lack of surrogate markers for immune protection against M. tuberculosis.

Source: Background

Abstract: What methods does the paper describe?

We investigated growth rates of M. tuberculosis in the mycobacterial growth inhibition assay (MGIA) as a marker for mycobacterial growth control of human bronchoalveolar lavage (BALC) and peripheral blood mononuclear cells (PBMC) before and after vaccination with Mycobacterium bovis Bacille Calmette: Guérin (BCG) of healthy adult volunteers.

Source: Methods

Abstract: Results

Vaccination induced a positive response (p < 0.001) to purified protein derivate (PPD) in 58.8% of the individuals in an interferon-γ release assay-ELISpot. Intraindividual evaluation of the MGIA growth rates before and after M. bovis BCG-vaccination revealed no significant difference in time to culture positivity before and after vaccination in BALC (p = 0.604) and PBMC (p = 0.199). The magnitude of the PPD-response induced by M. bovis BCG-vaccination did not correlate with growth control in BALC and PBMC (correlation = 0.468, 95% CI: −0.016 to 0.775).

Source: Results

Abstract: Conclusion

In conclusion, M. bovis BCG-vaccination-induced mycobacterial-specific cytokine immune response does not result in functional immune control against M. tuberculosis in the MGIA.

Source: Conclusion
Authors’ abstract

Background

In order to eliminate tuberculosis (TB), an effective vaccine is urgently needed to prevent infection with Mycobacterium tuberculosis. A key obstacle for the development of novel TB vaccines is the lack of surrogate markers for immune protection against M. tuberculosis.

Methods

We investigated growth rates of M. tuberculosis in the mycobacterial growth inhibition assay (MGIA) as a marker for mycobacterial growth control of human bronchoalveolar lavage (BALC) and peripheral blood mononuclear cells (PBMC) before and after vaccination with Mycobacterium bovis Bacille Calmette: Guérin (BCG) of healthy adult volunteers.

Results

Vaccination induced a positive response (p < 0.001) to purified protein derivate (PPD) in 58.8% of the individuals in an interferon-γ release assay-ELISpot. Intraindividual evaluation of the MGIA growth rates before and after M. bovis BCG-vaccination revealed no significant difference in time to culture positivity before and after vaccination in BALC (p = 0.604) and PBMC (p = 0.199). The magnitude of the PPD-response induced by M. bovis BCG-vaccination did not correlate with growth control in BALC and PBMC (correlation = 0.468, 95% CI: −0.016 to 0.775).

Conclusion

In conclusion, M. bovis BCG-vaccination-induced mycobacterial-specific cytokine immune response does not result in functional immune control against M. tuberculosis in the MGIA.

Publication and source details

Original title: Mycobacterium Growth Inhibition Assay of Human Alveolar Macrophages as a Correlate of Immune Protection Following Mycobacterium bovis Bacille Calmette: Guérin Vaccination

Juliane Radloff; Jan Heyckendorf; Lize van der Merwe; Patricia Sanchez Carballo; Norbert Reiling; Elvira Richter; Christoph Lange; Barbara Kalsdorf

Frontiers in Immunology · 2018

Edited by: Pere-Joan Cardona, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Spain

Reviewed by: Simone Joosten, Leiden University Medical Center, Netherlands; Michael Schotsaert, Icahn School of Medicine at Mount Sinai, United States

*Correspondence: Barbara Kalsdorf, bkalsdorf@fz-borstel.de

†Present address: Elvira Richter, MVZ Laboratory Dr. Limbach, Heidelberg, Germany

Specialty section: This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology

Copyright © 2018 Radloff, Heyckendorf, van der Merwe, Sanchez Carballo, Reiling, Richter, Lange and Kalsdorf.2018Radloff, Heyckendorf, van der Merwe, Sanchez Carballo, Reiling, Richter, Lange and Kalsdorfhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Deutsches Zentrum für Infektionsforschung10.13039/100009139

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T21:16:45.766029+00:00

DOI: 10.3389/fimmu.2018.01708 · PMC6066571